Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

@article{Hemmi2002SmallAC,
  title={Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway},
  author={Hiroaki Hemmi and Tsuneyasu Kaisho and Osamu Takeuchi and Shintaro Sato and Hideki Sanjo and Katsuaki Hoshino and Takao Horiuchi and Hideyuki Tomizawa and Kiyoshi Takeda and Shizuo Akira},
  journal={Nature Immunology},
  year={2002},
  volume={3},
  pages={196-200}
}
The imidazoquinoline compounds imiquimod and R-848 are low-molecular-weight immune response modifiers that can induce the synthesis of interferon-α and other cytokines in a variety of cell types. These compounds have potent anti-viral and anti-tumor properties; however, the mechanisms by which they exert their anti-viral activities remain unclear. Here we show that the imidazoquinolines activate immune cells via the Toll-like receptor 7 (TLR7)-MyD88–dependent signaling pathway. In response to… Expand
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
TLDR
It is demonstrated here that imiquimod induces activation of the transcription factor NF-kappaB and the downstream production of proinflammatory cytokines in the absence of TLR7 and TLR8, and appears to suppress an important feedback mechanism of inflammation by antagonism of adenosine receptor-dependent increase of cAMP and a concomitant receptor-independent inhibition of camp production. Expand
TLR7 and TLR8 as targets in cancer therapy
TLDR
The lead compound of the imidazoquinoline family, imiquimod, is marketed as a topical formulation that is efficacious against many primary skin tumors and cutaneous metastases and appears to be augmented by suppression of a regulatory mechanism, which normally limits inflammatory responses. Expand
Toll-like receptor signaling in anti-cancer immunity.
TLDR
It is demonstrated that TLR4 signaling is intimately involved in anti-cancer immunity induced by these immunopotentiators, and the clinical examination in oral cancer patients also suggests the requirement of bothTLR4 and MD-2 in the OK-432-induced anti- cancer host response. Expand
A Novel Small-Molecule Inhibitor of Endosomal TLRs Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models
TLDR
TAC5 and TAC5-a significantly hindered the activation of nuclear factor kappa-light-chain-enhancer of activated B cells, reduced the phosphorylation of mitogen-activated protein kinases, and inhibited the secretion of tumor necrosis factor-α (TNF-α) and interleukin-6 in mice. Expand
Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System
TLDR
Experiments indicated that repeated doses of a TLR7 ligand may desensitize dendritic cells in lymphoid organs, leading to diminished T cell responses, and might be a new modality to treat T cell mediated autoimmune diseases. Expand
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
TLDR
A novel TLR7 agonist is presented that induces pro-inflammatory cytokines in human blood cells, activates NK cell function, and is highly efficient in preventing lung metastases in a pulmonary metastatic Renca model. Expand
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia
TLDR
The potential importance of these TLR agonists in the treatment of CLL is suggested by their ability to sensitize tumor cells to cytotoxic agents, and their future probably lies in combination with radiotherapies, chemotherAPies, monoclonal antibodies and cancer vaccines. Expand
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice
TLDR
SC1 is a potent type-1 interferon inducer, comparable to the reference TLR7 agonist resiquimod, yet with lower induction of proinflammatory cytokines, and may form an attractive strategy to activate NK cell responses for cancer therapy. Expand
Small-Molecule Modulators of Toll-like Receptors.
TLDR
The progress in developing TLR signaling pathway modulators over the past decade is focused on and the accomplishments and currently existing challenges in the development of TLR modulators are highlighted. Expand
CHARACTERIZATION OF BIOLOGICAL FUNCTION OF INTERACTION BETWEEN TLR4 AND PLIC-1
TLDR
Results suggest that PLIC-1 is a negative regulator of TLR pathway, and this knowledge may be applied in immunotherapy as a means to modulate TLR activation in diseases such as septic shock, thus provides benefit for public health. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Molecular Mechanisms of B Lymphocyte Activation by the Immune Response Modifier R-8481
TLDR
The imidazoquinoline R-848, originally identified as a highly effective antiviral agent, has recently been shown to be capable of potent B lymphocyte activation, and it is demonstrated that this similarity extends to the intracellular signaling pathways triggered by the compound. Expand
The immune response modifier resiquimod mimics CD40-induced B cell activation.
TLDR
This study shows that resiquimod mimics effects of the T-dependent CD40 signal in both mouse and human B cell lines, and shows synergy with signals delivered by the B cell antigen receptor and heightens CD40-mediated B cell activation, demonstrating that resquimod can enhance antigen-specific responses in B lymphocytes. Expand
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.
TLDR
R-848 was shown to act as a vaccine adjuvant enhancing OVA-specific IgG2a levels while suppressing total IgE and indicates that R-8 48 and imiquimod are potent activators of B lymphocytes and are capable of augmenting antigen-specific immunoglobulin production. Expand
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus
TLDR
A common receptor activation pathway can initiate innate immune responses to both bacterial and viral pathogens. Expand
Unresponsiveness of MyD88-deficient mice to endotoxin.
TLDR
It is demonstrated that MyD88 knockout mice lack the ability to respond to LPS as measured by shock response, B cell proliferative response, and secretion of cytokines by macrophages and embryonic fibroblasts, and the inability of MyD 88 knockout mice to induce LPS-dependent gene expression cannot be attributed to lack of the activation of MAP kinases and NF-kappaB. Expand
A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.
TLDR
Two vaccinia virus ORFs are identified, termed A46R and A52R, that share amino acid sequence similarity with the Toll/IL-1 receptor (TIR) domain, a motif that defines the IL-1/Toll-like receptor (TLR) superfamily of receptors, which have a key role in innate immunity and inflammation. Expand
Discrimination of bacterial lipoproteins by Toll-like receptor 6.
TLDR
Results show that TLR6 recognizes MALP-2 cooperatively with TLR2, and appears to discriminate between the N-terminal lipoylated structures of MALp-2 and lipopeptides derived from other bacteria. Expand
Cutting Edge: Preferentially the R-Stereoisomer of the Mycoplasmal Lipopeptide Macrophage-Activating Lipopeptide-2 Activates Immune Cells Through a Toll-Like Receptor 2- and MyD88-Dependent Signaling Pathway1
TLDR
The MALP-2-induced activation of intracellular signaling molecules was fully dependent on both TLR2 and MyD88, and there was a strong preference for the R-MALP in the recognition by its functional receptor,TLR2. Expand
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
TLDR
The above results suggest that the imidazoquinolines R-848 and imiquimod may be attractive compounds for use as vaccine adjuvants and in inhibiting pathological responses mediated by Th2 cytokines. Expand
Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.
TLDR
The results indicate that imiquimod, similar to viral infection, stimulates expression of a large number of cytokine genes, including IFN-alpha/beta, and that the signal transduction pathway induced by both of these stimuli requires tyrosine kinase and protein kinase activity. Expand
...
1
2
3
4
5
...